## 1 Introduction
### Computing Influx
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Species** & **Membrane Proteins (Omp)** & \multicolumn{2}{c}{**Reported Antibiotic Study with (Omps)**} \\ \hline \multirow{10}{*}{_Klebsiella pneumoniae_} & & \(\bullet\) & Ceftazidine-Avibactam, Tigecycline, Colistin/OmpK36, \\  & & \(\bullet\) & CempK35 [122] \\  & & \(\bullet\) & Ceftazione, Imipenem, Ftrapenem, Novobiocin, Erythromycin, \\  & OmpK36 [112; 113; 113; 112], & Oxacillin, Cpxacillin, Cpxacillin, Cpxacillin, Benzylpenicillin, \\  & OmpK35 [27; 113; 112; 113; 113; 112] & Cedtazidine, Cepfelime/OmpK35, OmpK36 [112; 113] \\  & & \(\bullet\) & Ampicillin, Ticarcillin, Piperacillin, Ertapenem, Imipenem, \\  & & Meropenem, Cefotaxime, Cefepime, \\  & & Ceftazidine/OmpK36, OmpK35 [23]. \\ \hline \multirow{10}{*}{_Providencia staturti_} & OmpPst1 [119; 120], & \(\bullet\) & Ertapenem, Cefepime, Cefoxitin/OmpPst1 OmpPst2 [119] \\  & OmpPst2 [119] & \(\bullet\) & Carbapenem/OmpPst1 [121] \\ \hline \multirow{10}{*}{_Pseudomonas aeruginosa_} & (OpdC/OccD2, OprDOCp1, \\  & OpdP/OccD3, OpdB/OccD7, \\  & OpdI/OccD5, OpQ/OccD6, \\  & OpdT/OccD4, OpdPJ/OccD8) & \(\bullet\) & Fosfomycin/OprO, Oprp [165] \\  & [27; 33; 34; 125; 126; 130; 131; 132; 179], Opr & Meropenem,imipenem/OprD [140; 141; 142; 143] \\  & [34; 136; 137; 138; 152], OprO [152] & \(\bullet\) & Ceftazidine-Avibactam, Ceftolozane-Tazobactam/OprD [144] \\ \hline \hline \end{tabular} Note This table is a modified and updated version of the author’s previously published work Infection and Drug Resistance 2018:11 523-530 [45] and Infection and Drug Resistance 2017:10 261-273 [27] Adapted Originally published by and used with permission from Dove Medical Press Ltd.  
\end{table} 
Table 2: _Cont._ \begin{table}
\begin{tabular}{l l l l l} \hline \hline
**Molecules** & **Omps** & **Species** & \
\begin{tabular}{l} **Recalculated Flux at 1 \(\upmu\)M** \\ **Molecules/Second** \\ \end{tabular} &
\begin{tabular}{l} **Reported Flux** \\ **Molecules/Second** \\ \end{tabular} \\ \hline \multirow{2}{*}{Avibactam} & OmpF & _E. coli_ & 62 & \(\approx\)620 at gradient10 \(\upmu\)M [40] \\ \cline{2-5}  & OmpC & _E. coli_ & 23 & \(\approx\)229 at gradient10 \(\upmu\)M [37] \\ \hline \multirow{2}{*}{Tazobactam} & OmpF & _E.coli_ & 20 & \(\approx\)200 at gradient10 \(\upmu\)M [40] \\ \cline{2-5}  & OmpC & _E. coli_ & 20 & \(\approx\)200 at gradient10 \(\upmu\)M [37] \\ \hline \multirow{2}{*}{Sulbactam} & OmpF & _E. coli_ & 20 & \(\approx\)200 at gradient10 \(\upmu\)M [40] \\ \cline{2-5}  & OmpC & _E. coli_ & 18 & \(\approx\)187 at gradient10 \(\upmu\)M [37] \\ \hline \multirow{2}{*}{Fosfomycin} & OprO & _P. aeruginosa_ & 28 & \(\approx\)280 at gradient10 \(\upmu\)M [165] \\ \cline{2-5}  & OprP & _P. aeruginosa_ & \(\leq\)1 & \(\approx\)2.2 at gradient10 \(\upmu\)M [165] \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Reported turnover rates molecules/second at a given concentration gradient for different outer membrane proteins (Omps) with different substrates. The values are approximate, and for detailed calculations, please see the research publications mentioned with each value [26; 27; 39; 54; 153]. Substrates are shown in one column on the right, followed by reported porins, Gram-negative bacterial species, recalculated flux rates molecules/second at 1 \(\upmu\)M for comparison purposes only, approximate values, and Reported Flux Molecules/second at specifically mentioned gradient. The author has endeavored to gather as much data as possible, and the citations provided are accurate to the best of the knowledge. However, any errors in the citations or table are beyond the author’s control. Additionally, it should be noted that while this Table is included, the list may not be limited.